Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) EBT Margin (2016 - 2025)

Historic EBT Margin for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to 209.94%.

  • ImmunityBio's EBT Margin rose 11944500.0% to 209.94% in Q3 2025 from the same period last year, while for Sep 2025 it was 422.38%, marking a year-over-year increase of 75961700.0%. This contributed to the annual value of 2805.32% for FY2024, which is 910679900.0% up from last year.
  • As of Q3 2025, ImmunityBio's EBT Margin stood at 209.94%, which was up 11944500.0% from 349.31% recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's EBT Margin ranged from a high of 209.94% in Q3 2025 and a low of 735700.0% during Q1 2022
  • Moreover, its 5-year median value for EBT Margin was 57895.68% (2021), whereas its average is 131406.22%.
  • In the last 5 years, ImmunityBio's EBT Margin crashed by 2000000000bps in 2022 and then skyrocketed by 2000000000bps in 2023.
  • ImmunityBio's EBT Margin (Quarter) stood at 23474.87% in 2021, then tumbled by -532bps to 148345.21% in 2022, then fell by -13bps to 167952.52% in 2023, then skyrocketed by 100bps to 783.62% in 2024, then skyrocketed by 73bps to 209.94% in 2025.
  • Its EBT Margin stands at 209.94% for Q3 2025, versus 349.31% for Q2 2025 and 786.46% for Q1 2025.